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Introduction
Overactive bladder (OAB), with or without urinary
incontinence (UI), is a serious public health problem
in the United States and worldwide. OAB is deﬁned
by the International Continence Society (ICS) as
urgency, with or without urgency incontinence, usu-
ally with increased daytime frequency and nocturia (1).
Along with urgency urinary incontinence (UUI),
which is UI accompanied by urgency, another classi-
ﬁcation of UI is stress UI, which is deﬁned as UI
resulting from effort or exertion, or from sneezing or
coughing, and mixed UI, which is a combination of
UUI and stress UI (2). It is beyond the scope of
this review to address interventions for stress UI;
however, the interventions described herein may also
provide beneﬁt to these patients.
Overactive bladder is a prevalent condition; the
National Overactive BLadder Evaluation (NOBLE)
Program found that approximately 16% of men and
17% of women aged ‡ 18 years in the United States
are affected by OAB (3). More recently, the EPIC
study, which used the current ICS deﬁnition of OAB,
found that approximately 11% of men and 13% of
women in four European countries and Canada
reported OAB symptoms (4). Compared with other
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doi: 10.1111/j.1742-1241.2009.02078.x 1177common chronic diseases, the prevalence of OAB in
the United States population is higher than that of
diabetes (8%; 2003–2004) (5) and asthma (4.5%;
1988–1994) (6) and comparable to that of eczema
(17%) (7). Although the NOBLE and EPIC studies
found only slight gender differences in OAB preva-
lence, UUI is disproportionately more common in
women (3). Furthermore, the prevalence of OAB
does not differ signiﬁcantly between ethnic and racial
groups in clinic-based populations (8); however,
there is some evidence that UUI is more prevalent
among black women in population-based studies
(9–11).
Overactive bladder becomes more prevalent with
age (3,4). This is important because forecasts taken
from United Nations statistics predict that the pro-
portion of the population aged 65 years or older will
approximately double over the next two decades
(12). However, a considerable proportion of the
younger population also report OAB symptoms and
UUI (4).
Symptoms of OAB with or without UUI are both-
ersome and are associated with reduced health-
related quality of life (3,13,14). The impact of OAB
on the lives of both men and women is extensive
and includes detrimental effects on social, profes-
sional and recreational activities; sexual health and
function; and relationships with family members
(15–19). The impact of OAB on the social and func-
tional aspects of health-related quality of life may be
more severe than that of diabetes (14). OAB with or
without UUI is also associated with an increased risk
for several comorbidities, including depression, uri-
nary tract infection, skin infections, falls and frac-
tures and vulvovaginitis (3,20–23). Moreover, UUI
that can accompany OAB is associated with increased
rates of institutionalisation and mortality in older
patients (24,25). OAB symptoms and UI may also
precipitate adaptive changes in the behaviour of
those affected, including prophylactic urination
(termed defensive voiding), urination upon ﬁrst
desire, and ﬂuid restriction. Incontinence in general
has also been shown to be perceived by women as a
barrier to exercise (26).
Options for the treatment of OAB include
behavioural interventions, which are collectively con-
sidered ﬁrst-line treatments for OAB symptoms with
or without UI. Behavioural interventions are aimed
at changing patient lifestyle and behaviour and at
teaching techniques to suppress urgency and improve
continence skills. Behavioural interventions can be
readily prescribed in the primary care setting, either
before or concomitantly with pharmacotherapy
(27–35). Antimuscarinics, including darifenacin, feso-
terodine, oxybutynin, solifenacin, tolterodine and
trospium chloride, are pharmacological treatments
for OAB. Treatment options available for patients
with refractory OAB symptoms include botulinum
neurotoxin-A injections into the detrusor muscle;
surgical procedures (e.g. augmentation and urinary
diversion); neuromodulation, which involves stimula-
tion of the sacral nerves using implanted electrical
devices (36); and more recently, posterior tibial nerve
stimulation (37). These treatments are beyond the
scope of this review and will not be discussed further.
Behavioural interventions
Recommendations for behavioural interventions in
the treatment of OAB and UI have been published
by the International Consultation on Incontinence
(38), the American College of Obstetricians and
Gynecologists (39), the Society of Obstetricians and
Gynaecologists of Canada (40), the United King-
dom’s National Institute for Health and Excellence
(41) and the United States’ National Institutes of
Health (42). Behavioural interventions are well suited
to the primary care setting and can be conceptually
divided into two categories: the ﬁrst category
includes habits that may be modiﬁed to alleviate
bladder symptoms or promote bladder health and
the second includes training techniques aimed at
teaching skills to control the symptoms of bladder
dysfunction (Table 1). Healthy bladder habits include
lifestyle modiﬁcations (eliminating bladder irritants
from the diet, managing ﬂuid intake, weight control,
managing bowel regularity and smoking cessation)
and timed voiding regimens aimed at re-establishing
voiding at regular intervals. Patient education
regarding normal and abnormal bladder function is
helpful in the establishment of healthy bladder hab-
its. Training techniques include bladder training with
a progressive voiding schedule using relaxation and
distraction techniques for urgency suppression and
multicomponent behavioural training, in which
patients learn to use pelvic ﬂoor muscle (PFM) con-
traction to control urgency, and ultimately increase
the interval between voids, in addition to performing
PFM training (PFMT; Table 1).
The evidence supporting the use of these strategies
is strongest for behavioural training and bladder
training with and without PFMT for the treatment
of UUI (30,43–45). Whereas evidence supporting
lifestyle modiﬁcations is, as yet, relatively limited,
there is widespread clinical experience and interna-
tional expert opinion that support the use of life-
style modiﬁcations for the treatment of OAB and
UUI. While most of the literature discusses behavio-
ural interventions in the context of treatment for
bladder dysfunctions, information regarding lifestyle
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in primary care for educating patients in the mainte-
nance of good bladder and PFM function and per-
haps even for preventing future bladder problems
(46,47).
The educational materials included in Appendix 1
may be useful to both the primary care clinician
and the patient as an overview of behaviours to
promote bladder health and for the initiation of a
behavioural intervention. This focused patient-
friendly two-page educational pamphlet developed
by Pﬁzer Inc (New York, NY, USA) gives general
information about OAB, lifestyle modiﬁcations,
PFMT and urgency control strategies (48).
Healthy bladder habits and lifestyle
modiﬁcations
Patient education and counselling
The foundation of behavioural intervention is patient
education to enhance patients’ understanding of nor-
mal and abnormal bladder function, which then
serves as a basis for their understanding the speciﬁc
strategies that can be recommended for the preven-
tion and⁄or management of OAB and UUI. Chang-
ing bladder habits, making lifestyle changes and
adhering to the training techniques require patients
to make signiﬁcant behavioural changes in their daily
activities. It is essential to counsel patients on how
to best incorporate these strategies into their lives so
that adherence to behavioural interventions, and thus
an optimal treatment outcome, is more likely.
A bladder diary which is obtained at the initial
evaluation can be a useful tool in counselling patients
about their voiding behaviour and patterns (49).
Some individuals may be unaware of how often they
are voiding and they may be voiding to prevent
incontinence rather than responding to a need to
empty the bladder. The diary can also be used by
patients and clinicians for monitoring treatment pro-
gress and efﬁcacy. Typically, a bladder diary is kept
for 3–7 days and assesses voiding frequency and tim-
ing, the number of incontinent episodes and patients’
ﬂuid intake at initiation of treatment, so that progress
can be monitored. Bladder diaries can either be very
simple, recording the time of voluntary voiding and
Table 1 Behavioural interventions for managing urinary symptoms and promoting bladder health
Technique Description
Symptom
Frequency Urgency UUI MUI
Habit changes (managing symptoms and promoting bladder health)
Lifestyle modiﬁcation Diet, ﬂuid, bowel and weight management;
smoking cessation
XX X X
Timed voiding* Urination at a ﬁxed interval that avoids the
symptom (useful for urgency and UI not
associated with frequency)
XX X
Training techniques (managing symptoms)
Urgency control techniques Deep breathing and using complex mental
tasks (reciting poetry, counting backwards
from 100 by 7 s etc.) to ignore urgency
XX X X
Bladder training Progressively increasing interval between
voidings; utilises distraction and relaxation
techniques to gradually increase the time
between urinations
XX X X
Multicomponent behavioural
training*
Teaching to not rush to bathroom in
response to urgency and use of PFM
contractions to suppress bladder
contraction and delay voiding, with use
of pelvic ﬂoor muscle exercises
XX X X
Pelvic ﬂoor muscle training Daily regimen of pelvic ﬂoor muscle
contractions to maintain or build strength
and endurance
XX
Delayed voiding* Progressively increasing interval between
onset of urgency and voiding
XX X X
*Using a bladder diary. UUI, urgency urinary incontinence; MUI, mixed urinary incontinence; PFM, pelvic ﬂoor muscle.
Behavioural interventions for the treatment of OAB and UI 1179
ª 2009 The Authors
Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, August 2009, 63, 8, 1177–1191UUI episodes, or complex, recording episodes of
urgency, severity of urgency, voided volume per mic-
turition and type and amount of ﬂuid intake (Appen-
dix 2). An additional bladder record may be found in
the online version of this article (Appendix S1).
Timed voiding
Individuals who have urinary urgency and UUI may
be unaware of what constitutes an appropriate void-
ing schedule and may exacerbate their symptoms by
changing their voiding pattern. For adults who are
cognitively intact, physically capable of self-toileting
and capable of keeping bladder diaries, timed voiding
is recommended, which involves voiding on a ﬁxed
schedule irrespective of the need or desire to urinate
(50). Along with re-establishing a healthy voiding
schedule, timed voiding is also used as the basis of
bladder training (discussed in ‘Bladder training’).
Counselling patients that it is not necessary to void
with every bladder signal may itself provide new
information. Also important is teaching them that the
bladder should be emptied every 3–4 h. Habitually
ignoring the need to urinate may over-distend the
bladder and lead to bladder emptying problems. The
interval between urinations will be determined by
the patient’s bladder capacity, ﬂuid intake and activity
levels as well as environmental factors such as the
climatic conditions experienced by the patient and the
availability of a bathroom. In clinical practice, it may
be difﬁcult to persuade active and busy individuals to
comply with a rigid voiding schedule and thus, some
ﬂexibility in using this approach may be required.
Elimination of bladder irritants from the diet
Some foods and beverages are known to promote
diuresis or bladder irritability, which in some people
can exacerbate OAB symptoms and UUI. Caffeine in
particular has been shown to have a diuretic effect
(51) and is a constituent of a variety of beverages
and foods. Caffeine-containing products (foods and
ﬂuids) may increase OAB symptoms by increasing
detrusor pressure (52) and by promoting detrusor
muscle excitability (53).
Although the strength of the correlation of caffeine
intake with OAB symptoms and UI remains to be
resolved, the effects of caffeine are likely dose depen-
dent (54). Patients should therefore be queried for
their caffeine intake and advised of adverse effects of
caffeine on detrusor overactivity and of the potential
beneﬁts of reducing its intake. Patients should also
be advised to replace their caffeinated dietary intake
with non-caffeinated alternatives and to note any
changes in bladder symptoms. If there is no change
in bladder symptoms and if patients wish to con-
tinue to consume caffeine, they should be advised to
restrict this to < 200 mg⁄day (or two cups of coffee),
to decrease urgency and frequency (32). Caffeine is
also listed in labels for over 1000 over-the-counter
and prescription medications (55).
Other dietary factors that may contribute to OAB
symptoms and UUI include carbonated drinks in
women (56); there is some anecdotal evidence that
eliminating these from the diet may promote conti-
nence (32). There is also evidence to suggest that
aspartame and other artiﬁcial sweeteners induce
detrusor contraction in rats (57) and thus may
contribute to OAB symptoms.
Management of ﬂuid intake
Excessive ﬂuid intake can exacerbate OAB symp-
toms and incontinence, whereas restriction of ﬂuids
may result in an increase in urine concentration
that may irritate the bladder mucosa and promote
urgency, frequency and urinary tract infections (58).
Notably, it is common for clinicians to advise
patients to reduce ﬂuid intake to alleviate urinary
frequency, emphasising the need to assess the
patient’s current ﬂuid intake prior to making any
recommendations. An appropriate level of ﬂuid
intake is particularly important for older adults, for
whom a strong relationship between evening ﬂuid
intake and nocturia has been reported (59). The
daily volume of ﬂuid intake should be approxi-
mately six 8-oz glasses per 24 h (i.e. approximately
1500 ml or 30 ml⁄kg body weight per 24 h) (60).
To reduce nocturia, clinicians often advise patients
to reduce ﬂuid intake after 6 pm (or approximately
3–4 h before bedtime) and shift their intake to the
morning and afternoon, which anecdotally appears
to have good results (61).
Management of bowel regularity
Constipation is deﬁned clinically as passing < 3
stools per week; however, from the patient’s perspec-
tive, this deﬁnition also includes straining while pass-
ing a stool (61). In a study of constipation in
geriatric hospital patients, the prevalence of constipa-
tion was found to be directly correlated to UI (62).
Higher rates of constipation have also been found in
women and men with OAB than those without OAB
(19). Severely constipated women appear to have
changes in pelvic ﬂoor neurological function (63),
including denervation of the external anal sphincter
and PFMs (64). Alleviation of constipation has been
shown to signiﬁcantly improve urgency and fre-
quency in older patients (65).
Because chronic constipation is a likely risk factor
for OAB and UUI, patients can be advised of lifestyle
changes that alleviate the associated straining. These
may include self-care practices such as increasing
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ﬂuid intake, engaging in exercise and establishing a
routine defecation schedule. Patients should also be
advised not to ignore the urge to defecate, but rather
to respond promptly to the opportunity to move
their bowels.
Weight control
Obesity is associated with increased risk for the onset
of OAB symptoms (56), and having a body mass
index > 30 kg⁄m
2 is an independent risk factor for
OAB in women (66,67) and UI in older men (68).
Obesity has been hypothesised to promote UI by
increasing intra-abdominal pressure leading to
chronic stress on the pelvic ﬂoor that may lead to
overt structural damage and neurological dysfunction
resulting in UI (69). Surgical weight loss has been
shown to reduce UUI in women who are morbidly
obese (70). Even moderate weight loss has been
shown to improve UI symptoms in overweight
women (71–73). Thus, weight loss should be consid-
ered as a ﬁrst-line option for the treatment of UUI
in overweight women.
Smoking cessation
Research has shown that smoking is strongly associ-
ated with lower urinary tract symptoms in men (74–
76), with urgency (76) and with UUI in women
(77). This association may arise from the increases in
intra-abdominal pressure caused by chronic coughing
in smokers (77) or from increased detrusor activity,
which has been shown to be induced by nicotine in
the cat bladder (78). Smoking cessation may result in
decreased lower urinary tract symptoms in men (74);
however, there is currently no information on
whether this is true for women (76). Nevertheless,
both men and women who smoke should receive
education concerning the relationship between smok-
ing and UI and should be provided with strategies
for stopping, although there is currently a lack of
evidence that such strategies are effective.
Training techniques for managing OAB
symptoms and UUI
Simple urgency control and suppression
techniques
In the management of OAB symptoms, patients can
be taught to control urgency by performing general
relaxation techniques, including slow deep breathing
exercises to relax the bladder, decrease the intensity
of the urgency and allow the patient to delay voiding
and distraction techniques in which patients get
involved in tasks that involve mental concentration.
Examples include checkbook balancing, Sudoku or
crossword puzzles; and using self-motivational state-
ments, such as ‘I can wait’, ‘I can take control’ and
‘I will conquer this’ (79). If the patient is able to iso-
late and perform a PFM contraction, they can be
taught to suppress urgency by performing either a
10-s PFM contraction (80) or ﬁve or six rapid and
intense PFM contractions (see ‘Multicomponent
behavioural training’). These contractions appear to
induce their effects by preventing internal sphincter
relaxation produced by the micturition reﬂex, which
then results in detrusor relaxation (80). Although
strong PFM contractions will be more effective than
weak contractions in suppressing urgency, simply
making the patient aware of the importance of
a well-timed PFM contraction is likely to provide
beneﬁt.
Bladder training
The objective of bladder training is to restore normal
bladder function through the use of a progressive
voiding schedule in conjunction with teaching tech-
niques to control and suppress urgency. Bladder
training is a suitable treatment for OAB patients with
urgency, frequency and all types of UI who are moti-
vated to follow instructions (33,79). Studies using
bladder training have reported UI resolution ranging
from 12% to 73% and improvement rates ranging
from 57% to 87% (81). The technique can be easily
administered in an ofﬁce practice setting where the
patient is provided information about normal blad-
der function and instructions on methods to control
urgency discussed above. The patient is initially
instructed to follow a timed voiding schedule that
typically involves voiding every 30–60 min during
waking hours (31,38); these voiding intervals are
determined from baseline voiding frequency reported
in a bladder diary. The patient is instructed to keep
to the schedule regardless of urgency and to use
strategies to control urgency if this occurs before the
scheduled voiding time. Ideally, the voiding interval
should be increased by 15–30 min each week accord-
ing to the patient’s tolerance to the schedule, until a
voiding interval of at least 3–4 h is achieved. Use of
a bladder diary is recommended for self-monitoring
of progress (79). The urgency suppression techniques
described above can be implemented and provide
beneﬁt even if it is not feasible for a given patient to
follow a rigid voiding schedule.
Multicomponent behavioural training
Multicomponent behavioural training is a new
response to urgency based on the use of PFM con-
traction as a critical component to suppress urgency,
control incontinence and restore a normal voiding
interval. The efﬁcacy of behavioural training alone or
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frequency of UUI episodes and patient-reported out-
comes has been established in clinical trials (30,43–
45). Reductions in frequency of incontinence range
from 60% to 80% (29). One study reported a cure
rate of 31% for UI episodes in community-dwelling
women receiving a behavioural training regimen
(30), which is comparable with those reported for
pharmacotherapy with antimuscarinics (35).
The training regimen includes teaching patients
how to control the bladder by contracting the stri-
ated skeletal PFMs that surround the urethra (29,38).
Most patients with UUI report that they rush to the
bathroom when they sense the need to void. This
type of behavioural training instructs patients to
resist the normal tendency to rush because it
increases intra-abdominal pressure, and that being
near the toilet may actually trigger detrusor contrac-
tion. Patients are taught instead to stay still, sit down
if possible, contract their PFMs several times to help
relax the detrusor, wait for their urgency to subside
and only then to walk at a normal pace to the bath-
room.
Another component of this intervention is the
practice of daily PFM exercises to improve strength
and skill. Patients are provided with speciﬁc instruc-
tions on how to locate their PFM, as well as verbal
feedback during a pelvic examination (using vaginal
or anal palpation), because 50% of women are
unable to achieve this with simple verbal or written
instruction alone (82). A useful approach is to ask
patients to imagine trying to prevent the passing of
gas or pinching off a stool by tightening the ring of
muscles around the anus without tensing the muscles
of the legs, buttocks or abdomen; this should result
in a closing and lifting sensation. Men can be asked
to imagine moving the penis up and down without
moving any other part of the body. Once the patient
is able to isolate the PFM, the daily PFMT regimen
includes 45 exercises which are divided into sets of
15 exercises, three times a day. The patient should be
encouraged to gradually increase the duration of the
contraction to a maximum of 10 s, with an equal
period of relaxation between contractions (43).
Patients should be advised to practice in various
positions including lying, sitting and standing. To
promote adherence, clinicians should help patients
establish a routine schedule for incorporating the
three PFMT sets into their daily lives. For example,
the exercises could be scheduled before regular activ-
ities such as before meals. Scheduling PFMT at spe-
ciﬁc times is a more effective strategy than
remembering to perform exercise on an ad hoc sche-
dule (83). For optimal efﬁcacy, PFMT may need to
be continued for 8–12 weeks (35). Similar to all
muscles, PFMs require continuous exercise to remain
strong once they are rehabilitated.
Behavioural interventions to improve outcomes
of pharmacotherapy
Multicomponent behavioural training with urgency
suppression techniques have been shown to enhance
the effectiveness of pharmacotherapy for OAB (29).
Thus, although antimuscarinics effectively inhibit
detrusor contraction, patients may not be able to
become continent without actively controlling
urgency symptoms. For example, it has been
reported that the addition of oxybutynin to a
behavioural training regimen, and vice versa, yielded
additional treatment beneﬁt for older women with
UUI who were not satisﬁed with the results of each
therapy alone (84). Another study showed that the
addition of multicomponent behavioural training to
drug therapy reduced UUI episodes in women with
OAB (85). However, this study also demonstrated
that the behavioural training regimen did not
increase the number of participants who could dis-
continue drug therapy while maintaining improve-
ments in UUI, suggesting that behavioural training
alone might not replace pharmacotherapy as a treat-
ment for UI.
Evidence is accruing that behavioural interventions
consisting of simple educational materials combined
with verbal reinforcement from clinicians can
improve OAB symptoms and increase patient satis-
faction with pharmacotherapy. For example, combin-
ing a brief handout on bladder training and
treatment with tolterodine was shown to signiﬁcantly
reduce the voiding frequency and increase the voided
volume per micturition in participants with OAB
compared with tolterodine treatment alone (n = 501)
(45). Another study showed that signiﬁcantly more
participants receiving tolterodine in combination
with an educational intervention either started or
continued with drug treatment and reported an
improvement in bladder symptoms, compared with
those receiving tolterodine alone (n = 138) (86). A
recent open-label study showed that combining
tolterodine extended release with a simple self-
administered behavioural intervention (Appendix 1)
consisting of an educational pamphlet with monthly
verbal reinforcement of the information resulted in
high treatment satisfaction and improved OAB
symptoms in participants who were dissatisﬁed with
their most recent antimuscarinic OAB therapy
(n = 416) (48). Participants in this study cited the
information received on the causes of OAB and
treatments available to improve bladder control as an
important contributor to their treatment satisfaction
(87). The results support the notion that many
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become satisﬁed with the use of a tailored self-
administered behavioural intervention. By contrast, a
randomised parallel-group study reported that
improvements in OAB symptoms and health-related
quality of life elicited by darifenacin treatment were
not enhanced by the addition of a self-administered
behaviour modiﬁcation programme (n = 395) (88).
However, this study did not specify dissatisfaction
with prior antimuscarinic treatment as an inclusion
criterion, and the behavioural programme used mul-
tiple pamphlets and multimedia materials, contrast-
ing with the focused written intervention used in the
open-label tolterodine extended release study.
Treatment pathways
Ideally, the treatment with the lowest risk should be
recommended ﬁrst in the treatment for OAB and
UUI (89,90). Although behavioural interventions are
associated with minimal risk, they can unfortunately
be perceived as being time intensive and too difﬁ-
cult to implement in a busy ofﬁce setting, especially
when bladder symptoms become severe before they
are recognised. Routine questioning of patients
about voiding patterns would allow for symptoms
to be recognised at an early point when information
about healthy bladder habits could be optimally
provided by the clinician. Screening for bladder
symptoms is also important because of the negative
impact that OAB symptoms and UI may have on
other high priority conditions such as urinary tract
infections, diabetes, obesity and hypertension.
Scheduling a speciﬁc ofﬁce visit to discuss bladder
health issues and having the patient bring in a
completed bladder diary would be an effective strat-
egy in addressing any issues that might have been
raised in a previous visit. The simple educational
intervention described in this review (Appendix 1)
could also enhance treatment outcomes for these
other conditions and increase the value of the time
invested by the clinician. This brief handout or sim-
ilar material could easily be implemented by either
a physician or a nurse. The key point is that the
clinician invests the time educating patients about
their condition and counsels them about strategies
to manage their symptoms. It is important to keep
in mind that treatment for other conditions and
concomitant medical conditions may contribute to
OAB symptoms, especially in older adults (91).
Therefore, before adding another medication, it is
important to ensure that an existing medication(s)
is not contributing to the patient’s symptoms. If so,
this should be taken into account when tailoring a
behavioural intervention strategy.
In selecting the type of therapy to be used for the
treatment of OAB and UUI, it is of paramount that
clinicians gauge the patient’s treatment preferences,
motivations, expectations and goals. The decision to
begin behavioural interventions before or with medi-
cations is driven by clinician and patient preference.
Some patients may want to experience quick treat-
ment results and may not be receptive to behavioural
intervention. In these cases, the optimal treatment
option may be to prescribe an antimuscarinic in
combination with education about lifestyle factors
that can be changed to alleviate their OAB symptoms
and UUI. Patients presenting with OAB symptoms
should be taught skills for responding adaptively to
urgency, including relaxation techniques, distraction
techniques, PFM contractions and staying away from
the bathroom until the urgency has subsided rather
than rushing to the toilet. Bladder training or timed
voiding can be especially helpful for patients whose
symptoms include frequent urination. A guide to
applying the techniques discussed in this review to
the treatment of OAB symptoms and UUI is pro-
vided in Table 1. Additional information is available
from the organizations listed in Appendix 3.
For the patient, the success of a lifestyle modiﬁca-
tion or behavioural intervention process, with or
without pharmacological therapy, may depend on
receiving adequate support from their healthcare pro-
vider. Clinicians should follow-up with patients regu-
larly to monitor their progress and determine
whether the treatment regimen is effective and satis-
factory to the patient, or whether adjustments need
to be implemented. If the patient is not responding
satisfactorily to these ﬁrst-line therapies, they can be
referred to a continence specialist for evaluation and
treatment. Urodynamic evaluation may be indicated
for those with complex symptomatology. Patients
who are having difﬁculty isolating their PFMs and
desire behavioural intervention should be referred to
a physical therapist, a continence nurse specialist, or
a nurse practitioner for a more intensive behavioural
intervention programme using biofeedback training
and⁄or pelvic ﬂoor electrical stimulation. Biofeedback
is a teaching technique that allows patients to moni-
tor their PFM contractions and relaxations by provid-
ing immediate physiological feedback of PFM activity
in an understandable visual and⁄or audible format
(32). It has been shown that biofeedback-assisted
behavioural training with PFMT in combination with
education about strategies to control urgency reduced
UI episodes by approximately 80%, which was greater
than that observed for drug therapy alone in older
women (44). Pelvic ﬂoor electrical stimulation
involves the application of low-power electrical stim-
ulation to the PFMs to induce a contraction of these
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contractions associated with OAB (32).
Conclusion
Behavioural interventions can readily be incorporated
into the daily lives of patients who possess the
cognitive and functional capability; clinicians and
staff in busy ofﬁce settings can readily incorporate
these therapies into routine medical and nursing
care. Although OAB symptoms and UUI can be
successfully managed using non-pharmacological
approaches, they require considerable motivation
from the patient and attrition rates may be high
without adequate follow up, although attrition may
also occur because of lack of efﬁcacy. Behavioural
interventions which educate and empower patients
can be utilised either alone or as an adjunct therapy
to enhance pharmacotherapy for OAB and UUI.
However, the issue of whether it is optimal to initiate
treatment using a combined therapy or to start with
a single therapy and then introduce a second
approach if the patient does not respond to treat-
ment remains to be resolved and may be largely dri-
ven by patient preference until more evidence is
available. Finally, clinicians should be familiar with
the practical details of habit changes and training
techniques not only to optimise treatment outcomes
in consideration of patient preferences and goals for
OAB treatment, but also as the foundation for
patient education to promote bladder health as part
of routine healthcare.
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Appendix 1 Educational handout. Male and female versions of the OAB patient education sheet are available at http://
www.pﬁzerpro.com/toviaz in the patient education section
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Time interval
Urinated
in toilet
Amount of urine
leakage
Reason for
urine leakage
Changed wet pad
Type⁄amount
of liquid intake hL hM hS hD hW hS
Sample   hL  M hS rushing to toilet hD hW  S
6a m hL hM hS hD hW hS
7a m hL hM hS hD hW hS
8a m hL hM hS hD hW hS
9a m hL hM hS hD hW hS
10 am hL hM hS hD hW hS
11 am hL hM hS hD hW hS
Noon hL hM hS hD hW hS
1p m hL hM hS hD hW hS
2p m hL hM hS hD hW hS
3p m hL hM hS hD hW hS
4p m hL hM hS hD hW hS
5p m hL hM hS hD hW hS
6p m hL hM hS hD hW hS
7p m hL hM hS hD hW hS
8p m hL hM hS hD hW hS
9p m hL hM hS hD hW hS
10 pm – Midnight hL hM hS hD hW hS
Midnight – 2 am hL hM hS hD hW hS
2–4 am hL hM hS hD hW hS
4–6 am hL hM hS hD hW hS
ª Diane K. Newman.
Directions
Column 1: Time interval.
Column 2: Next to the correct time interval, place a checkmark ( ) next to time urinated.
Column 3: Mark every time you have urine leakage and indicate whether the amount was large (L), moderate (M) or
small (S).
Column 4: Record the reason for the urine leakage, such as sneezing, lifting, coughing, laughing, could not make it to the
bathroom, and so on.
Column 5: Place a checkmark ( ) each time a wet pad was changed. Mark how wet: ‘D’ if the pad is slightly wet or damp,
‘W’ if wet, and ‘S’ if the pad is saturated or very wet.
Column 6: In the correct time interval, describe your liquid intake (e.g. coffee, water and orange juice) and estimate the
amount (e.g. one cup or 8 oz).
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Alliance for Ageing Research 2021 K St. NW, Suite 305
Washington, DC 20006
(202)293-2856
http://www.agingresearch.org
American College of Obstetricians and Gynecology (ACOG) 409 12th, SW
Washington, DC 20024
(202) 638-5577
http://www.acog.com
American Urological Association Foundation (AUAF) 1000 Corporate Boulevard
Linthicum, MD 21090
(866) 746-4282
http://www.auafoundation.org/
American Physical Therapy Association Section on Women’s Health
111 N. Fairfax St.
Alexandria, VA 22314
(703) 684-2782
http://www.apta.org
American Urogynecologic Society (AUGS) 2025 M St. NW, Suite 800
Washington, DC 20036
(202) 367-1167
http://www.augs.org
American Urological Association (AUA) 1120 N. Charles St.
Baltimore, MD 21201
(410) 727-1100
http://www.auanet.org
Association of Women’s Health, Obstetric and Neonatal Nurses 2000 L St. NW, Suite 740
Washington, DC 20036
(800) 673-8499
http://www.awhonn.org
International Continence Association 19 Bristol Square
Bristol
Bristol BS2 8SJ
UK
(44) 117 944881
http://www.icsofﬁce.org
National Association for Continence (NAFC) PO Box 1019
385 Meeting St., Suite 100
Charleston, SC 29402
(800) 252-3337
http://www.nafc.org
National Institute of Diabetes and Digestive and Kidney Disease
(NIDDK)
National Institutes of Health
Westwood Building, Suite 3A-05
Bethesda, MD 20892
http://www.niddk.nih.gov
Simon Foundation for Continence Box 835-F
Wilmette, IL 60092
(800) 237-4666
http://www.simonfoundation.com
Society of Urologic Nurses and Associates (SUNA) East Holy Avenue, Box 56
Pitman, NJ 09071-0056
(888) 827-7862
http://www.suna.org
Wound, Ostomy and Continence Nurses Society (WOCN) 4700 West Lake Avenue
Glenview, IL 60025
(800) 224-9626
http://www.wocn.org
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Additional Supporting Information may be found in
the online version of this article:
Appendix S1. Bladder record
Please note: Wiley-Blackwell are not responsible
for the content or functionality of any supporting
materials supplied by the authors. Any queries (other
than missing material) should be directed to the cor-
responding author for the article.
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